Research programme: epigenetic modulators - Oryzon

Drug Profile

Research programme: epigenetic modulators - Oryzon

Alternative Names: LSD1 inhibitors - Oryzon; ORY 3001

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Oryzon
  • Class Small molecules
  • Mechanism of Action Enzyme modulators; Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Inflammation; Viral infections

Most Recent Events

  • 21 Dec 2016 Early research in Inflammation in Spain (unspecified route)
  • 30 Nov 2015 Early research in Cancer in Spain (unspecified route) before November 2015
  • 24 Jan 2012 Early research is ongoing in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top